Important New Research using Immunocal® Shows Promise in Lou Gehrig’s Disease

Immunotec Inc. announces that data from research using Immunocal® in a mouse model by Principal Investigator Daniel Linseman, PhD and his team at the University of Denver in Colorado shows promise in delaying the onset of amyotrophic lateral sclerosis. Investigators studied mice harbouring the gene that is responsible for some forms of the disease commonly known as ALS or Lou Gehrig's disease, a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. The data demonstrates for the first time that supplementation with Immunocal may be effective in preserving blood glutathione levels which typically diminish in affected mice. Immunocal, a whey protein isolate, is Immunotec’s flagship product. Click here to read the entire media release.

http://www.immunotec.com/IRL/images/Immunocations/Facebook/2011-06-13_ALS_ENG.FINAL.pdf